Y S Yoon1, J Kim2, S-M Hong2, J L Lee1, C W Kim1, I J Park1, S-B Lim1, C S Yu1, J C Kim1. 1. Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. 2. Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Abstract
AIM: Colorectal cancer (CRC) with microsatellite instability (MSI) is characterized by frequent poor differentiation or mucinous histology. The purpose of this study was to evaluate the association of MSI with clinicopathological features and the oncological outcome in patients with a mucinous component. METHOD: CRC tissue samples were analysed for histology and MSI. Patients were grouped according to the mucinous content of the tumour, as follows: > 50%, mucinous adenocarcinoma (MA); ≤ 50%, adenocarcinoma with mucinous component (AMC); none, nonmucinous adenocarcinoma (NMA). Clinicopathological parameters and survival were compared between patient groups. RESULTS: Of 2025 patients, 84 (4%) had MA and 124 (6%) had AMC. In addition, 202 (10%) had MSI. Patients with MA and AMC tended to have a younger age of onset, right-colon predilection, large-sized tumour and high frequency of MSI compared with those with NMA (P < 0.001). MA and AMC patients with MSI showed a trend towards right-colon predilection and infrequent lymph-node metastasis compared with those with microsatellite stability (MSS; P = 0.005-0.03). There were no survival differences between the three groups, but patients with MSI-MA demonstrated lower 4-year recurrence and better overall survival rates than those with MSS-MA (P = 0.018 and P = 0.046, respectively). CONCLUSION: Clinicopathological features of AMC and MA were similar and closely associated with MSI status. Although the prognoses of AMC and MA were no different from that of NMA, survival of patients with an MSI-MA tumour was significantly better than for those with MSS-MA tumours. Colorectal Disease
AIM: Colorectal cancer (CRC) with microsatellite instability (MSI) is characterized by frequent poor differentiation or mucinous histology. The purpose of this study was to evaluate the association of MSI with clinicopathological features and the oncological outcome in patients with a mucinous component. METHOD:CRC tissue samples were analysed for histology and MSI. Patients were grouped according to the mucinous content of the tumour, as follows: > 50%, mucinous adenocarcinoma (MA); ≤ 50%, adenocarcinoma with mucinous component (AMC); none, nonmucinous adenocarcinoma (NMA). Clinicopathological parameters and survival were compared between patient groups. RESULTS: Of 2025 patients, 84 (4%) had MA and 124 (6%) had AMC. In addition, 202 (10%) had MSI. Patients with MA and AMC tended to have a younger age of onset, right-colon predilection, large-sized tumour and high frequency of MSI compared with those with NMA (P < 0.001). MA and AMCpatients with MSI showed a trend towards right-colon predilection and infrequent lymph-node metastasis compared with those with microsatellite stability (MSS; P = 0.005-0.03). There were no survival differences between the three groups, but patients with MSI-MA demonstrated lower 4-year recurrence and better overall survival rates than those with MSS-MA (P = 0.018 and P = 0.046, respectively). CONCLUSION: Clinicopathological features of AMC and MA were similar and closely associated with MSI status. Although the prognoses of AMC and MA were no different from that of NMA, survival of patients with an MSI-MA tumour was significantly better than for those with MSS-MA tumours. Colorectal Disease
Authors: Christoph Jakob Ackermann; Ulrich Guller; Wolfram Jochum; Bruno M Schmied; Rene Warschkow Journal: Int J Colorectal Dis Date: 2018-06-07 Impact factor: 2.571
Authors: Yunghuyn Hwang; Yong Sik Yoon; Jun Woo Bong; Hye Yun Choi; In Ho Song; Jong Lyul Lee; Chan Wook Kim; In Ja Park; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim Journal: Ann Coloproctol Date: 2019-08-31
Authors: James W T Toh; Stephanie H Lim; Scott MacKenzie; Paul de Souza; Les Bokey; Pierre Chapuis; Kevin J Spring Journal: Cells Date: 2020-02-12 Impact factor: 6.600
Authors: Lauren C Bylsma; Christina Gillezeau; Tamer A Garawin; Michael A Kelsh; Jon P Fryzek; Laura Sangaré; Kimberly A Lowe Journal: Cancer Med Date: 2019-12-19 Impact factor: 4.452
Authors: David S Williams; Dmitri Mouradov; Marsali R Newman; Elham Amini; David K Nickless; Catherine G Fang; Michelle Palmieri; Anuratha Sakthianandeswaren; Shan Li; Robyn L Ward; Nicholas J Hawkins; Iain Skinner; Ian Jones; Peter Gibbs; Oliver M Sieber Journal: Mod Pathol Date: 2020-02-11 Impact factor: 7.842